December 31, 2013 | Hadasit Bio-Holdings, the commercialization branch of Hadassah Medical Center, has received NIS 25 million (approx. $7.2 million) from the Office of the Chief Scientist. The funds will be directed towards three of Hadasit’s portfolio companies: Cell Cure, KAHR Medical and Enlivex Therapeutics.
Related posts
$10M For Cyber Company That Protects Small Businesses
January 31, 2023
Phone-Block Technology For School Bus Drivers
January 31, 2023
Israeli Patients Can Now WhatsApp Their Doctor
January 31, 2023
People With Autism Experience Higher Intensity Pain
January 30, 2023
Facebook comments